Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more
Invion Limited (IVIXF) - Net Assets
Latest net assets as of December 2025: $3.81 Million USD
Based on the latest financial reports, Invion Limited (IVIXF) has net assets worth $3.81 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.40 Million) and total liabilities ($1.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.81 Million |
| % of Total Assets | 70.55% |
| Annual Growth Rate | -5.53% |
| 5-Year Change | 50.98% |
| 10-Year Change | 108.23% |
| Growth Volatility | 145.58 |
Invion Limited - Net Assets Trend (2014–2025)
This chart illustrates how Invion Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Invion Limited (2014–2025)
The table below shows the annual net assets of Invion Limited from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $5.43 Million | -62.39% |
| 2024-06-30 | $14.44 Million | +17.84% |
| 2023-06-30 | $12.25 Million | -9.31% |
| 2022-06-30 | $13.51 Million | +275.63% |
| 2021-06-30 | $3.60 Million | -3.87% |
| 2020-06-30 | $3.74 Million | -2.31% |
| 2019-06-30 | $3.83 Million | -34.44% |
| 2018-06-30 | $5.84 Million | +400.87% |
| 2017-06-30 | $1.17 Million | -55.28% |
| 2016-06-30 | $2.61 Million | -61.99% |
| 2015-06-30 | $6.86 Million | -32.47% |
| 2014-06-30 | $10.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Invion Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2831619100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $99.52 Million | 1832.64% |
| Other Comprehensive Income | $1.04 Million | 19.21% |
| Other Components | $1.00 | 0.00% |
| Total Equity | $5.43 Million | 100.00% |
Invion Limited Competitors by Market Cap
The table below lists competitors of Invion Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CATCo Reinsurance Opps C
LSE:CATC
|
$2.07 Million |
|
Royal Wins Corporation
PINK:RYWCF
|
$2.07 Million |
|
China ZhengTong Auto Services Holdings Limited
PINK:CZASF
|
$2.07 Million |
|
Antelope Enterprise Holdings Ltd
NASDAQ:AEHL
|
$2.07 Million |
|
Silver Wolf Exploration Ltd
OTCQB:SWLFF
|
$2.07 Million |
|
NORDSON
BE:ND1
|
$2.07 Million |
|
Visionary Education Technology Holdings Group Inc.
NASDAQ:GV
|
$2.07 Million |
|
The Calmer Co International Ltd
AU:CCO
|
$2.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Invion Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,437,672 to 5,430,269, a change of -9,007,403 (-62.4%).
- Net loss of 5,796,848 reduced equity.
- Share repurchases of 170,302 reduced equity.
- New share issuances of 3,950,400 increased equity.
- Other comprehensive income decreased equity by 1,119,809.
- Other factors decreased equity by 5,870,844.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.80 Million | -106.75% |
| Share Repurchases | $170.30K | -3.14% |
| Share Issuances | $3.95 Million | +72.75% |
| Other Comprehensive Income | $-1.12 Million | -20.62% |
| Other Changes | $-5.87 Million | -108.11% |
| Total Change | $- | -62.39% |
Book Value vs Market Value Analysis
This analysis compares Invion Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.49x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.19x to 0.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | $0.19 | $0.04 | x |
| 2017-06-30 | $0.07 | $0.04 | x |
| 2018-06-30 | $0.15 | $0.04 | x |
| 2019-06-30 | $0.07 | $0.04 | x |
| 2020-06-30 | $0.07 | $0.04 | x |
| 2021-06-30 | $0.07 | $0.04 | x |
| 2022-06-30 | $0.22 | $0.04 | x |
| 2023-06-30 | $0.19 | $0.04 | x |
| 2024-06-30 | $0.22 | $0.04 | x |
| 2025-06-30 | $0.08 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Invion Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -106.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.15x
- Recent ROE (-106.75%) is below the historical average (-68.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -67.76% | -3320.17% | 0.01x | 1.45x | $-7.90 Million |
| 2015 | -190.10% | -7035.81% | 0.01x | 2.35x | $-13.73 Million |
| 2016 | -127.00% | 0.00% | 0.00x | 3.42x | $-3.57 Million |
| 2017 | -144.67% | 0.00% | 0.00x | 3.82x | $-1.80 Million |
| 2018 | -61.60% | -660.17% | 0.07x | 1.31x | $-4.18 Million |
| 2019 | -19.50% | -27.41% | 0.64x | 1.11x | $-1.13 Million |
| 2020 | -17.55% | -27.44% | 0.60x | 1.06x | $-1.03 Million |
| 2021 | -30.96% | -63.65% | 0.41x | 1.18x | $-1.47 Million |
| 2022 | -11.45% | -68.09% | 0.16x | 1.02x | $-2.90 Million |
| 2023 | -8.78% | -39.34% | 0.22x | 1.04x | $-2.30 Million |
| 2024 | -38.98% | -228.53% | 0.16x | 1.07x | $-7.07 Million |
| 2025 | -106.75% | 0.00% | 0.00x | 1.15x | $-6.34 Million |
Industry Comparison
This section compares Invion Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Invion Limited (IVIXF) | $3.81 Million | -67.76% | 0.42x | $2.07 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |